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INTRODUCTION
Cervical cancer is the second most common malignancy in women worldwide [1] . The incidence of cervical cancer in young women has been increasing recently. Cervical intraepithelial neoplasia (CIN) is a precancerous lesion that can be treated effectively to prevent progression to cervical cancer. CIN 1 lesions are usually followed up without treatment; however, 10% of CIN 1 lesions progress to CIN 3 or cervical cancer. In patients of CIN 2, 20% of CIN 2 lesions progress to CIN 3 or cervical cancer, and 40% of CIN 2 lesions regress spontaneously [2] .
For many gynecologists, the management of patients with CIN 1-2 is controversial [2] : should they observe patients until spontaneous regression or treat patients with ablative or excisional procedures? Although it may be appropriate to treat only patients that are at high risk of progression, and to observe low risk patients that may regress spontaneously, it is not easy to predict the outcome of each patient. There is a growing need to establish an effective biomarker that would serve as a reliable predictor of the outcomes.
One of the important biomarkers for CIN and cervical cancer is the human papillomavirus (HPV) genotyping. HPV DNA is found positive in more than 90% of cervical cancer patients [3] , and especially, high-risk genotypes of HPV are considered to be associated with development of CIN and cervical cancer [3] [4] [5] . It has been shown that HPV genotyping can detect women with cytological abnormalities and it has a potential role in identifying women at risk of residual or recurrent disease after treatment of CIN [6] . However, HPV genotyping is less specific than cytology, because many infections regress without progressing to high-grade lesions and a positive HPV test does not necessarily discriminate between transient and chronic infection [7, 8] .
Previous experimental and epidemiologic studies have shown that expression of E6 and E7 genes of the high-risk genotypes of HPV in the squamous epithelial cells of the uterine cervix may result in neoplastic growth, and that infection with high-risk HPV results in the expression of p16 INK4a [9, 10] . p16
INK4a is one of the cyclin-dependent kinase inhibitors that prevents phosphorylation of retinoblastoma protein (Rb) and therefore plays an important role in the regulation of the mammalian cell cycle [11] . www.ejgo.org 217
Definition of CIN progression and regression
Progression was defined as the appearance of histologically confirmed CIN 3 or more during the follow-up period. We defined regression as at least two consecutive conventional cytology with normal colposcopical findings. Women were regarded as having persistent lesions when they did not have either regression or progression over the follow-up period [17] .
p16
INK4a immunohistochemistry and interpretation of results All samples were prepared from colposcopically directed punch biopsy specimens. The immunohistochemistry was performed as follows. Formalin-fixed and paraffin-embedded specimens were stained on a Dako Autostainer (Dako Norden A/S, Glostrup, Denmark) using a CINtec p16
INK4a Histology
Kit for the DakoCytomation Autostainer according to the manufacturer's instructions. Briefly, antigen retrieval was performed by heating in a water bath at 95 o C for 20 minutes. After blocking endogenous peroxidase activity, the slides were incubated with primary antibody (E6H4 clone). Then, a secondary antibody reagent for visualization was employed from the above-mentioned kit. The slides were incubated with DAB (3,3'-diaminobenzidine). Substrate-chromogen solution and counterstaining was performed with Mayer's hematoxylin before coverslipping.
The evaluation of immunoreactivity was reported previously. Briefly, immunoreactivity was evaluated on the basis of nuclear and/or cytoplasmic staining, 1) evaluation of the staining intensity: -, no staining; +, weak staining; ++, moderate staining; +++, strong staining, and 2) evaluation of the percentage of positively stained cells in each section. Immunoreactivity for p16
INK4a was then classified as negative, weakly positive, moderately positive, and strongly positive ( Table 1 , Fig. 2 ). The p16 INK4a overexpression rate was calculated by adding the number of moderately and strongly positive specimen.
HPV genotyping by polymerase chain reaction
The procedure of HPV genotyping has been described previously [18, 19] . Briefly, genomic DNA was extracted from exfoliated cells, using proteinase K and phenol-chloroform treatment. The specimens were tested for the presence of HPV DNA by polymerase chain reaction (PCR) analysis with consensus primer pairs (L1C1 and L1C2) designed to amplify an approximately 250-bp segment of the viral DNA. The consensus primer pairs target the HPV L1 open reading frame and detect a broad range of genital HPVs. The HPV genotyp- The difference in the regression rate between these two groups was also significant (p=0.003) (Fig. 4) . The HPV genotyping of 131 patients with CIN 1-2 revealed infection by the following sixteen HPV genotypes; 6, 16, 18, 31, 33, 35, 51, 52, 56, 58, 59, 68, 70, 71, 84, and 90. In this study, we defined HPV16, 18, 31, 33, 35, 51, 52, 56, and 58 as high-risk HPVs prevalent in Japanese women [18, 20, 21] . Among 201 patients who were tested with HPV genotyping, 162 patients (80.0%) were identified to have infection with high-risk HPV genotypes. The rate of infection with high-risk HPV also increased with increasing CIN grade, with significant differences between CIN 1 (65.1%) and CIN 2-3 lesions (87.7%) (p<0.001). Among the patients, 73 had infection with prevalent highrisk HPV, 10 had infection by other genotypes of HPV (6, 59, 68, 70, 71, 84), 26 were negative for HPV infection, and 32 were not tested for the HPV infection status. Although www.ejgo.org 219 patients infected with prevalent high-risk HPV showed a higher tendency towards progression of the CIN lesions, there was no significant difference in the rate of progression of the lesions between high-risk HPV-positive and negative groups (Fig. 4 ). There were also no significant differences in the rate of progression or regression of the lesions between patients infected with HPV 16 or 18 and those infected with neither of these HPV genotypes (p=0.60) ( Table 2) . Among 76 patients with CIN 1, 58 patients were evaluated for HPV genotyping. The associated HPV genotypes with CIN 1 patients were 16, 18, 31, 33, 35, 51, 52, 56, 58, 59, 68, 70, 84, and 90. There was also no significant difference in the rate of progression and regression between high-risk HPV-positive and negative groups among the CIN 1 patients according to the Kaplan-Meier analysis (p=0.951, p=0.652, respectively). However, clinical information was limited because they only selected CIN 1 patients that showed regression or progression to CIN 3, not including persistent patients. Here in this study, we evaluated both CIN 1 and CIN 2 patients for their outcomes The cumulative regression rate and follow-up periods (mo) for patients with CIN 1-2 with high-risk HPV infection. The regression rate in the patients with prevalent high-risk HPV was not significantly different from that in patients who were negative for high-risk HPV infection. The definition of progression/persistence and regression was described in the manuscript. CIN, cervical intraepithelial neoplasia.
DISCUSSION

